Peptron
Financials
Valuation Metrics
Peptron's Market Cap is ₩3.1T. At end of 2025 it was ₩5.9T. Ranked #153 of 2,419 in KR market (top 6%), #25 of 1,638 on KOSDAQ (top 2%), #10 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.05T KRW | KR#153/2,419 Sec#10/231 |
| Revenue | 6.00B KRW | KR#2,323/2,419 Sec#188/231 |
| Net Income | -20.53B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 167.98B KRW | KR#1,427/2,419 Sec#109/231 |
| Net Assets | 129.48B KRW | KR#1,239/2,419 Sec#95/231 |
| Employees | 112 | KR#1,557/2,419 Sec#121/231 |
| Value | ||
| P/B | 23.59x | KR#2,402/2,419 Sec#225/231 |
| P/S | 509.02x | KR#2,405/2,419 Sec#222/231 |
| FCF Yield | -0.76% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -15.86% | KR#2,036/2,419 Sec#156/231 |
| ROA | -12.22% | KR#2,146/2,419 Sec#163/231 |
| Op. Margin | -427.48% | KR#2,358/2,419 Sec#202/231 |
| Revenue Growth | 15.87% | KR#657/2,419 Sec#60/231 |
| Financial Health | ||
| Debt Ratio | 29.74% | KR#587/2,419 Sec#67/231 |
| Total Debt | 30.28B KRW | KR#1,225/2,419 Sec#94/231 |
| FCF | -23.08B KRW | KR#1,930/2,419 Sec#186/231 |
| Cash | 12.31B KRW | KR#1,569/2,419 Sec#129/231 |
| Current Ratio | 9.11x | KR#119/2,419 Sec#28/231 |
| Performance | ||
| 1Y Return | -56.41% | KR#2,192/2,419 Sec#207/231 |
| 1M Return | -18.23% | KR#2,301/2,419 Sec#220/231 |
| From 52W High | -66.62% | KR#2,127/2,419 Sec#182/231 |
| 1Y MDD | -73.16% | KR#2,113/2,419 Sec#186/231 |
| Trading | ||
| Volume | 208,221 shares | KR#511/2,419 Sec#62/231 |
| Trading Value | 27.39B KRW | KR#140/2,419 Sec#13/231 |
| Foreign Own. | 4.60% | KR#926/2,419 Sec#82/231 |
| Per Share | ||
| EPS | -881 KRW | KR—/2,419 Sec—/231 |
| BPS | 5,553 KRW | KR#1,423/2,419 Sec#101/231 |
Company Info
Peptron, established in 1997 for biotechnology advanced material manufacturing and pharmaceutical R&D, was listed on KOSDAQ in 2015. The company develops pharmaceuticals based on peptide engineering and drug efficacy sustaining original technology, securing clinical trial and commercialization capabilities through GMP mass production facilities. With its SmartDepot technology, Peptron can develop various pharmaceuticals, accelerate its contract drug development and manufacturing business, and conduct research on metabolic disease treatments and anticancer drugs. The company is headquartered in Yuseong-gu, Daejeon.